He says that Biogen would like to take the MS cure science and apply it to a wider group of neurodegenerative diseases....that would mean using 2-73's homeostasis properties to treat Alzheimers. And consequently, it would require Biogen to buy the whole 2-73 franchise. It is obvious that any current offer to Anavex in not substantial enough, but with success in any of the three trials, IMHO Biogen will have to significantly up the ante of fold. Then who among the "Big Boys" will call.
Totally agree w/this assessment. The curious thing to me has been what will trigger the (seemingly certain) next steps??? A demonstration as proof by trial of CNS disease efficacy? All the pieces are there now, is it a simple matter of DENIAL?Do they believe the science or not? This is where leadership matters.This is NOT A DRILL.
Market Data 
Markets 
